Send a text

Send a text

Enterprise AI is not a tool decision. It is an operating model decision.

In this episode of The Signal Room, Chris Hutchins sits down with Gary Cao, Chief Data & Analytics / AI Officer, to explore the enterprise AI journey from an executive perspective.

This conversation moves beyond hype and definitions. Instead, it focuses on what actually changes inside an organization when AI becomes strategic:

• Moving from AI experimentation to enterprise maturity
• Integrating generative AI into structured data environments
• Deterministic systems vs. probabilistic reasoning
• The role of semantic layers and data management bottlenecks
• Automation vs. agentic AI systems
• Measuring enterprise ROI in an era of high abandonment rates

Gary shares practical insight into AI maturity models, governance design, risk tolerance tiers, and the evolving role of the CDAO in coordinating strategy, technology, and accountability.

If you are a board member, C-suite executive, data leader, or digital transformation officer navigating AI at scale, this episode provides a grounded view of what it takes to move from ambition to enterprise execution.

Connect with Gary Cao on LinkedIn:
https://www.linkedin.com/in/garycao/

Subscribe to The Signal Room for conversations at the intersection of leadership, governance, and AI innovation.

Support the show

Support the show

Send a text

AI ambition isn’t the problem in healthcare. Execution is.

In this episode of The Signal Room, Chris Hutchins sits down with Brian Sutherland, Lead AI Product Manager and advisor specializing in customer-facing AI for high-consequence healthcare environments.

Brian built Humana’s first member-facing Intelligent Virtual Assistant — generating $7M+ in annual savings while improving patient experience and task completion. In this conversation, we move beyond AI hype and examine what actually breaks between executive strategy and operational reality.

We explore:

• Why AI pilots succeed but enterprise adoption stalls
• Trust as infrastructure — not philosophy
• The leadership shift required as AI embeds into clinical workflows
• Where hype is outrunning evidence in healthcare AI
• What responsible scale actually looks like

If you are a healthcare executive, board member, digital health leader, or AI product owner, this episode is a grounded discussion on what it takes to move from ambition to accountable execution.

Connect with Brian Sutherland on LinkedIn:
https://www.linkedin.com/in/briandsutherland/

Subscribe for practical conversations at the intersection of leadership, ethics, and healthcare innovation.

Support the show

Send a text

AI is transforming drug discovery—but faster models alone do not get drugs approved.

In this episode of The Signal Room, host Chris Hutchins speaks with David Finkelshteyn, CEO of Pivotal AI, about why verification—not speed or model accuracy—is the real bottleneck in pharmaceutical AI.

David explains why generating AI-designed molecules without rigorous validation creates more risk than value, especially in regulated environments like pharma and healthcare. The conversation breaks down where AI outputs most often fail between discovery and regulatory acceptance, why black-box models struggle under scrutiny, and what it actually means to verify an AI insight in drug development.

They also explore practical challenges around data integrity, auditability, missing context, hallucinations, and the growing use of consumer AI tools in health decisions. Rather than chasing hype, this episode focuses on how AI can responsibly accelerate drug development by failing faster, tightening verification loops, and building systems that can be defended to regulators, auditors, and clinicians.

This episode is essential listening for leaders working in pharmaceutical R&D, healthcare AI, data science, AI governance, and regulated technology environments.

Guest: David Finkelshteyn, CEO, Pivotal AI
LinkedIn: https://www.linkedin.com/in/david-finkelshteyn-03191a130/

Support the show